Disease · MONDO_0019461

B-cell prolymphocytic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. B-cell prolymphocytic leukemia. Diseases, record MONDO_0019461. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019461

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: B-cell prolymphocytic leukemia; Open Targets
Open Targets ID: MONDO_0019461; Open Targets
Other names: B prolymphocytic leukaemia, B prolymphocytic leukemia, B-PLL; Open Targets
Disease Ontology: DOID:0081041; Disease Ontology
MeSH: D054403; MeSH
NCI Thesaurus: C4753; NCI Thesaurus
Orphanet: ORPHA:86852; Orphanet
Highest stage of its drugs: Phase 2, for 4 of its 11 drugs, from ClinicalTrials.gov; Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
IBRUTINIB	CHEMBL1873475	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DINACICLIB	CHEMBL2103840	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
OFATUMUMAB	CHEMBL1201836	Antibody	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDARABINE PHOSPHATE	CHEMBL1096882	Small molecule	Phase 1	ClinicalTrials.gov	2	2	2	Drugs and targets
ALVESPIMYCIN HYDROCHLORIDE	CHEMBL2105630	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
BENDAMUSTINE HYDROCHLORIDE	CHEMBL1201734	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ETOPOSIDE	CHEMBL44657	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets23

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	2	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
BTK	Tyrosine-protein kinase BTK	1	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
CDK1	Cyclin-dependent kinase 1	1	Cyclin-dependent kinase 1 inhibitor	Phase 1/2	https://conductscience.org/library/genes/983	Drugs and targets
CDK2	Cyclin-dependent kinase 2	1	Cyclin-dependent kinase 2 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1017	Drugs and targets
CDK5	Cyclin-dependent kinase 5	1	Cyclin-dependent kinase 5 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1020	Drugs and targets
CDK9	Cyclin-dependent kinase 9	1	Cyclin-dependent kinase 9 inhibitor	Phase 1/2	https://conductscience.org/library/genes/1025	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 1	https://conductscience.org/library/genes/5425	Drugs and targets

1 to 10 of 23

See all 23 targets

Trials7

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01589302	PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia	Phase 2	154	2019-05-21	Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia	IBRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT01515176	Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Phase 1/2	36	2018-03-15	Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia	DINACICLIB, OFATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT02303392	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Phase 1	34	2025-06-10	Prolymphocytic Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia	IBRUTINIB, SELINEXOR	Its record names the disease	ClinicalTrials.gov
NCT05418088	Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	Phase 1	54		Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent High Grade B-Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory High Grade B-Cell Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Non-Hodgkin Lymphoma	CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT02153580	Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia	Phase 1	37		B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma	BENDAMUSTINE HYDROCHLORIDE, CYCLOPHOSPHAMIDE, ETOPOSIDE, FLUDARABINE PHOSPHATE	Its record names the disease	ClinicalTrials.gov
NCT01126502	Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Phase 1	30		B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia	ALVESPIMYCIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00281931	Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia	Phase 2	21		Prolymphocytic Leukemia	CYCLOPHOSPHAMIDE, FLUDARABINE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dose Level I: Treatment (Ofatumumab, Dinaciclib) vs Dose Level II: Treatment (Ofatumumab, Dinaciclib): Number of Patients With Dose-limiting Toxicity Incidents Graded According to the NCI CTCAE v4.0 (Phase I)	0 of 4	0 of 32	36	NCT01515176	Trial comparisons
Dose Level I: Treatment (Ofatumumab, Dinaciclib) vs Dose Level II: Treatment (Ofatumumab, Dinaciclib): deaths from any cause	0 of 4	1 of 32	36	NCT01515176	Trial comparisons
Dose Level I: Treatment (Ofatumumab, Dinaciclib) vs Dose Level II: Treatment (Ofatumumab, Dinaciclib): serious adverse events	3 of 4	32 of 32	36	NCT01515176	Trial comparisons
Chronic Lymphocytic Leukemia (CLL) vs Non-Hodgkin Lymphoma (NHL): deaths from any cause	1 of 16	4 of 18	34	NCT02303392	Trial comparisons
Chronic Lymphocytic Leukemia (CLL) vs Non-Hodgkin Lymphoma (NHL): serious adverse events	6 of 16	7 of 18	34	NCT02303392	Trial comparisons

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
34608724	DERIVED	1	PubMed
34492703	DERIVED	1	PubMed
28714866	DERIVED	1	PubMed
26182309	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0019461

GET https://conductscience.org/api/diseases/v1/MONDO_0019461/targets?page=2

API reference For AI assistants